Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl) methylene)-2-oxoindolin-5-yl)N8- hydroxyoctanediamide 6
Patel, H., Chuckowree, I., Coxhead, P., Guille, M., Wang, M., Zuckerman, A., et al. (2014). Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors. MEDCHEMCOMM, 5(12), 1829-1833 [10.1039/c4md00211c].
Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors
LIBRIZZI, Mariangela;
2014-01-01
Abstract
Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl) methylene)-2-oxoindolin-5-yl)N8- hydroxyoctanediamide 6
| File | Dimensione | Formato | |
|---|---|---|---|
|
file.pdf
Solo gestori archvio
Dimensione
302.63 kB
Formato
Adobe PDF
|
302.63 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
